The present pilot study aims to evaluate the frequency and the function of regulatory T (Treg) cells in patients with diffuse cutaneous SSc (dcSSc) before and after autologous hematopoietic SCT (aHSCT). Peripheral blood lymphocytes from seven dcSSc patients were analyzed before and 24 months after aHSCT and were compared with those from seven healthy donors (controls).
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Immunophenotyping of CD4
þ CD25 high FoxP3 þ natural Treg (nTreg), CD4 þ CD25 þ TGF-b þ and CD4 þ CD25 þ IL-10 þ adaptive Treg (aTreg) cell subsets was performed using four-color flow cytometry. Treg-suppressive capability was measured after coculture with autologous T effector cells by evaluation of T-cell proliferation using 3 þ CD25 high CD127 low were restored to the levels in controls. The decreased frequency and the functional defect of peripheral Treg cells from patients with dcSSc are reversed following aHSCT to reach those observed in controls. This pilot study brings evidence of an effective restoration of nTreg and aTreg subsets, and recovery of nTreg suppressive function following aHSCT.
INTRODUCTION
Systemic sclerosis (SSc) is a chronic autoimmune disease with a heterogeneous clinical presentation. Although its exact pathogenesis is still unknown, it is characterized by alterations of the microvasculature, disturbances of the immune system with high production of autoantibodies and progressive fibrosis of the skin and internal organs. 1 Whatever the original stimulus, abnormal immune stimulation, production of autoantibodies and cytokine release may be, 2 all contribute to increased collagen synthesis and deposition, fibroblast activation and microvascular damage. Several studies have highlighted the key role of the adaptive immune response in SSc patients, 3 as evidenced by infiltration of activated CD4 þ and CD8 þ T cells in skin tissues, lung interstitium and bronchio-alveolar fluids and in peripheral blood. 4 T regulatory (Treg) cells represent 5-10% of the peripheral CD4 þ T cells in humans 5 and can be characterized by the expression of CD4, CD25 and Foxp3, a transcription factor critical to the development of natural Treg (nTreg) cells, 6 namely CD4 þ CD25 high FoxP3 þ . Two major subsets of Treg cells have been described: a nTreg population developing in the thymus and an adaptive Treg (aTreg) subset developing in the periphery under particular conditions of suboptimal antigen exposure and/or costimulation. The aTreg cells, which include CD4 þ CD25 high Foxp3 þ and CD4 þ CD25 high Foxp3 À T cells, are generated from mature T-cell populations (classical T-cell subsets or nTreg cells) after antigenic stimulation. 7 The aTreg cells mediate their inhibitory activities by producing immunosuppressive cytokines, such as TGF-b and IL-10. 2, 7 The various Treg cells have key roles in maintaining self-tolerance and modulating the allergic and autoimmune responses, while controlling autoreactive T cells. [8] [9] [10] [11] Several studies have reported a deficiency in the number of Treg and/or function in autoimmune disease patients, 12, 13 
high CD127 low subsets. 22 Despite these controversies, in most of these studies of SSc patients' samples, 22, 23, 26 impaired Treg-suppressive function was associated with SSc disease severity. Of interest, Klein 1 et al. 26 reported that there was a reduction in Treg within the skin, but not in the peripheral blood of SSc patients.
Use of autologous hematopoietic SCT (aHSCT) has recently been shown to induce long-term remission in severe or rapidly progressive diffuse cutaneous SSc (dcSSc), with rapid and sustained regression of skin and lung fibrosis, and improved functional status. 27, 28 After aHSCT, the clinical regression of skin fibrosis has been correlated with reappearance of functional B cells, thymic and extrathymic T-cell development, reconstitution of effector cells and efficient antigen presentation to reconstitute the pretransplantation immune repertoire. 29, 30 However, further analysis of the immune reconstitution of the various Treg subsets and their function after aHSCT in SSc patients is warranted.
To address this issue, the present pilot study aimed to analyze the respective levels of Treg subsets in SSc patients before and after aHSCT, and the suppressive functions of these cells from SSc patients as compared with those from healthy donors.
PATIENTS AND METHODS Patients
Seven patients (mean age 46±18 years) with early rapidly progressive dcSSc), defined according to the American Rheumatism Association criteria, 31 were enrolled for receiving aHSCT treatment (Department of Internal Medicine, St Louis Hospital). The transplant procedure and followup were performed as previously described. 28 Written informed consent was obtained and each protocol was approved by the local ethics committee of the St Louis Hospital institute. Table 1 provides an overview of the patients' clinical characteristics. As controls, venous blood was collected from seven healthy donors (four males, three females) of the same age range as that of SSc patients (39 ± 16 years), recruited by the Etablissement Franc¸ais du Sang after informed consent. Peripheral blood cells were isolated by Ficoll-Hypaque centrifugation followed by elimination of monocytes by adhesion for 2 h. Treg subpopulations from SSc patients and their suppressive capacity were analyzed before and 24 months after aHSCT and results were compared with controls.
Flow cytometry analysis
Peripheral blood lymphocyte (PBL) samples were stimulated for 5 days with anti-CD3 antibody, anti-CD28 antibody and IL2, and during the last 5 h, PMA (0.2 mg/mL), Ionomycin (1 mg/mL) and GolgiStop (BD Biosciences, San Josè , CA, USA) were added to the cultures. Monoclonal antibodies conjugated with either fluorescein isothiocyanate (FITC), phyco-erythrin (PE) or allophycocyanin (APC) and directed to CD4, CD25, IL-10, TGF-b (BD Biosciences), Foxp3 (eBiosciences, San Diego, CA, USA) or matched isotype controls were used for immunophenotyping and intracellular staining, according to the manufacturer's protocols. Evaluation of Treg subpopulations by flow cytometry was determined as CD25 bright
FoxP3
þ percentage expression within the CD3 þ CD4 þ compartment. aTreg percentages were CD4 þ TGF-b-or IL-10-producing aTregs. Data from patients (n ¼ 7) and controls (n ¼ 7) were acquired and analyzed on a four-parameter flow cytometer FACSCalibur using ProCellQuest software (BD Biosciences). À T cells) in a 96-well plate previously coated with anti-CD3 and anti-CD28 antibodies. Cocultures were assessed with Teff to Treg ratio ranging from 1:1 to 3:1. After 5 days of culture, cell proliferation was measured by incorporation of 3 H-thymidine radioactive (37 mBcq/mL/well) during the last 18 h. The percentage of cell proliferation inhibition was calculated as (1 À (% of proliferating target T cells in coculture with Treg cells)/(% of proliferating target T cells cultured alone)) Â 100.
Statistical analysis
All results are expressed as mean±s.d. Statistical significance for all experiments was assessed using the paired Student's t-test. Differences were considered as significant at Po0.05.
RESULTS

Frequency of peripheral CD4
þ CD25 high FoxP3 þ nTreg cells in SSc patients before and after aHSCT As detected by flow cytometry analysis, we observed a significant decrease in the percentage of CD4 þ CD25 high FoxP3 þ nTreg cells in SSc patients evaluated before aHSCT (2±0.5, n ¼ 7) as compared with the respective percentage in healthy donors (4.2 ± 1.1, n ¼ 7, Po0.01; Figure 1a ). Figure 1b represents the fluorescence-activated cell sorting (FACS) dotplots for one representative healthy donor (left panel) and one SSc patient before any treatment (middle panel).
To investigate whether aHSCT induced reconstitution of the various Treg subsets in SSc patients, we compared the percentage of nTreg cells from SSc patients before and after aHSCT versus those from healthy donors. As shown in Figure 1a The mean percentage of CD4 þ CD25 þ TGF-b þ T cells was significantly lower in SSc patients (6.9±1.8, n ¼ 3) compared with healthy donors (14.6 ± 5.0, n ¼ 7, Po0.05), as shown in Figure 2c . Twenty-four months after aHSCT, the mean percentage of CD4 þ
CD25
þ TGF-b þ T cells remained significantly lower than in controls, although it was increased (17.2±4.5, data not shown) in two patients studied at 48 months after aHSCT. In Figure 2d , FACS dotplots are presented for one representative healthy donor (left panel), as well as in one SSc patient before aHSCT (middle panel) and 24 months after (right panel) aHSCT. Taken together, (Figure 3b, blue dots) . At higher dilutions, the percentage of suppression correlated with the Teff:Treg cell ratio. In contrast, Treg cells from SSc patients exhibited a significantly reduced suppressive capacity compared with those from healthy donors (Po0.05), suppressing the proliferation of CD4 þ target T cells by a mean percentage of 59.8 ± 16.1 (n ¼ 3) at ratio 1:1 (Figure 3b, red dots) . This low inhibitory effect was maintained up to a dilution of 3:1 Teff:Treg. The suppressive activity of Treg cells from SSc patients 24 months after aHSCT (83.4±11.7 at ratio 1:1, n ¼ 3, Figure 3b , green dots) was significantly higher compared with their mean suppressive capacity before aHSCT (Po0.05). These results clearly indicated that aHSCT can restore the suppressive activity of Treg cells in SSc patients, in parallel with regression of skin fibrosis as shown by a fall in Rodnan skin score for each patient at 24 months (Table 1) .
DISCUSSION
The present pilot study illustrates, for the first time to our knowledge, that aHSCT allowed restoration of the levels of both nTreg and aTreg subsets in this small group (n ¼ 7) of SSc patients. In addition, our results confirmed that dcSSc patients have significantly decreased levels of circulating CD4 þ TGF-b þ T cells. 20, 21 In contrast to our study, Klein et al.
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recently showed no significant difference in the frequency of CD4 þ CD25 high FoxP3 þ from SSc patients as compared with healthy donors. This discrepancy might be due to systemic treatment with corticosteroids and/or cyclophosphamide, which might have restored the frequency of Treg in the studied SSc patients, as described in human lupus erythematous. 32 Nevertheless, the authors reported a decrease in cutaneous Treg content that might be essential during the early phase of cutaneous disease.
To determine the regulatory potential of the natural Treg cells in SSc patients, we performed functional suppressor assays using a new biomarker as an alternative to Foxp3. Indeed, most studies have identified CD127 as a viable surface marker that could distinguish highly suppressive Treg (CD127 low ) cells from Teff (CD127 high ) cells in humans. 33 These new sorting parameters for Treg avoid contamination with activated T cells that expressed intermediate levels of CD25. Our results demonstrate that CD4 þ CD25 high CD127 low Treg cells functions were impaired in SSc patients as compared with normal healthy controls, and also that suppressive functions were effectively restored 24 months after aHSCT. This clearly indicates that aHSCT can restore immunological selftolerance in dcSSc patients who could recover suppressive function of Treg cells similar to normal, as previously found by Zhang et al. 34 in 15 HSCT lupus patients studied before and after aHSCT.
Few studies with different methods, each of them in a small number of patients, have analyzed the immune reconstitution process after aHSCT for various types of autoimmune disease, including multiple sclerosis, 35 SSc, 29, 30 juvenile arthritis 36 and SLE. 37 All studies reported that long-term remission in patients who received aHSCT was associated with a de novo regeneration of the T-cell compartment that can be delayed for years after T-cell depleting conditioning for aHSCT. In particular, they demonstrated a drastic reactivation of thymic activity reflected by the increased T-cell receptor excision circle (TREC) levels, as well as an increased thymic output as evidenced by the increased diversity of TCRB CDR3 repertoire. The immune reconstitution process after aHSCT is associated with the reemergence of naive T cells, the depletion of autoreactive memory T cells, the regeneration of thymic-derived FoxP3 þ regulatory T cells and the recovery of the naive B-cell compartment. 29, 30, 35, 38 Two important observations for SSc patients treated by aHSCT emerged from the present pilot study: first, both nTreg and aTreg cells regenerated to frequencies comparable with those in normal controls; second, the renewal of Treg subsets was associated with a restoration of nTreg suppressive capacity, as reported by Zhang et al. 34 in SLE patients treated by aHSCT. Altogether, our data support the 'resetting' of the adaptive immune system induced by aHSCT, as previously reported for other types of autoimmune diseases treated by aHSCT and always based on the analysis of a small number of patients. 29, 34, 36, 37 To further prove the specific relationship to SSc, these results have to be compared with aHSCT effects on a population of patients receiving transplantation for another indication.
Therefore, aHSCT could be used as a therapeutic intervention in several autoimmune diseases in which Treg functions are impaired, such as SLE, lupus or type I diabetes. Future studies are needed to evaluate the mechanisms by which Tregsuppressive functions could be altered in SSc and restored by aHSCT. Alteration might be attributed to either an impaired suppressor function of the Treg cells from SSc patients or a resistance to suppression by SSc Teff cells, as previously demonstrated in SLE. 39 This resistance has been attributed to pro-inflammatory cytokines such as tumor necrosis factor-a, interleukin (IL)-6, IL-7 and IL-1b. 40, 41 Further investigation in a larger cohort of patients with dcSSc treated by aHSCT as compared with standard therapy, such as those included ASTIS or SCOTT trials, the still ongoing large phase III randomized trials, 42 will help to answer these questions and to correlate encouraging results from the present pilot study with patient clinical parameters and remission. 
